Basit öğe kaydını göster

dc.contributor.authorMengi, Gönen
dc.contributor.authorGöğüş, Feride
dc.date.accessioned2020-11-20T14:55:07Z
dc.date.available2020-11-20T14:55:07Z
dc.date.issued2017
dc.identifier.issn1309-0291
dc.identifier.issn2148-5046
dc.identifier.urihttps://doi.org/10.5606/ArchRheumatol.2017.6055
dc.identifier.urihttps://hdl.handle.net/20.500.12809/2207
dc.descriptionWOS: 000396544400012en_US
dc.descriptionPubMed ID: 30375550en_US
dc.description.abstractAnti-tumor necrosis factor alpha (anti-TNF-alpha) therapy has been widely used for the management of rheumatologic diseases. The most frequent adverse effects of anti-TNF-alpha therapy are infections and malignancies while sarcoidosis is a rare condition. On the other hand, anti-TNF-alpha therapy has been used in the treatment of sarcoidosis. Elucidation of this paradoxical issue is unclear. In this article, we report an ankylosing spondylitis patient who was diagnosed as sarcoidosis during the period of etanercept usage. Sarcoidosis as a possible adverse effect should be kept in mind during anti-TNF-alpha therapy.en_US
dc.item-language.isoengen_US
dc.publisherTurkish League Against Rheumatismen_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdverse Effecten_US
dc.subjectAnti-Tumor Necrosis Factor Alpha Therapyen_US
dc.subjectSarcoidosisen_US
dc.titleA Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosisen_US
dc.item-typearticleen_US
dc.contributor.departmentMÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.identifier.doi10.5606/ArchRheumatol.2017.6055
dc.identifier.volume32en_US
dc.identifier.issue1en_US
dc.identifier.startpage67en_US
dc.identifier.endpage70en_US
dc.relation.journalArchives of Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster